NeuroClues

NeuroClues is a MedTech company operating in the digital health sector with a clear focus on early diagnosis of neurological disorders. Founded in 2021 by a team that includes Antoine Piron, the company aims to address the growing prevalence of conditions like Parkinson's, Alzheimer's, and Multiple Sclerosis. The core of their business is the development of a diagnostic tool that leverages eye-tracking technology to detect subtle, involuntary eye movements. These movements serve as digital biomarkers, potentially enabling clinicians to identify these debilitating diseases years before the onset of visible motor symptoms. The company's technology is delivered through a software platform that utilizes a simple webcam, making it an accessible and scalable solution for healthcare providers.

The business model appears to be centered on providing this diagnostic platform as a service to clinicians and healthcare systems in the European Union and the United States. NeuroClues seeks to function as a 'stethoscope for the brain,' offering a non-invasive and pragmatic tool that can be integrated into regular clinical practice. By providing quantitative and objective data, the platform supports neurologists in making earlier and more accurate diagnoses. This early detection is critical, as it opens a window for interventions that could slow disease progression and improve patient outcomes. The founding team's background combines experience in MedTech entrepreneurship and medical practice, providing a foundation of both technical and clinical expertise to navigate the complex healthcare market.

NeuroClues has secured initial funding to advance its technology, including a significant pre-seed round that involved investors such as The Faktory and various business angels. The company maintains operational bases in Louvain-la-Neuve, Belgium, Paris, France, and New York, USA, reflecting its international ambitions. Their strategy involves actively seeking partnerships with investors, Key Opinion Leaders, and companies to facilitate market entry and adoption of their novel diagnostic approach. The ultimate goal is to shift the paradigm in neurology from late-stage symptom management to early, data-driven intervention. Keywords: digital biomarkers, neurological disorders, eye-tracking, early diagnosis, MedTech, Parkinson's disease, Alzheimer's disease, clinical decision support, neurology, digital health